Ph.D. Vimal Mehta - 15 Jun 2026 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Reporting relationship: CEO and President, Director
Issuer ticker: BTAI
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 20:00:06 UTC
Prior SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Richard Steinhart, Attorney-in-Fact for Vimal Mehta, Ph.D.

Key filing fact

Ph.D. Vimal Mehta filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 17 Jun 2026.

Key facts

This page summarizes Ph.D. Vimal Mehta's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 20:00.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001733369 Primary reporting owner

Mehta Vimal

Relationship: CEO and President, Director
Address: C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN
Signature: /s/ Richard Steinhart, Attorney-in-Fact for Vimal Mehta, Ph.D.
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BTAI transaction

Common Stock

Options Exercise

Transaction value
Shares: +219
Change %: +0.31%
Price
Shares after: 69,817
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1

BTAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 125
Date: 15 Jun 2026
Ownership: By Spouse

BTAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 480,343
Date: 15 Jun 2026
Ownership: By BioXcel LLC
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BTAI transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -219
Change %: -14%
Price: $0.000000^*
Shares after: 1,313
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 219
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Footnote F3

On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.